Proia, Theresa A.
2AstraZeneca, Waltham, Massachusetts.
2 papers on CoChatORCID 0009-0000-4572-5118
Most cited papers
- Verified
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Pore, N., Wu, S., Standifer, N., Jure-Kunkel, M., de los Reyes, M., Shrestha, Y., Halpin, R., Rothstein, R., Mulgrew, K., Blackmore, S., et al. (2021) · Cancer Discovery
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 88
- Verified
Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications
Melanoma and MAPK PathwaysCell death mechanisms and regulation
Cited by 80
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free